Articles By Mrinalini Dey, MD

lupus.nephritis.immunofluorescence.jpg

Obinutuzumab drives histologic remission in lupus nephritis

By Mrinalini Dey, MD

At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.

Read Article
abstract

New JAK inhibitors in the axSpA treatment landscape

By Mrinalini Dey, MD

At EULAR 2026, two large phase 3 studies highlight that the JAK story in axSpA is still evolving rapidly, with different selectivity profiles and expanding global development programs continuing to push the field forward.

Read Article
Lung.Pleural.inflamm.AI

RA-ILD: Screening risk and genetic susceptibility

By Mrinalini Dey, MD

RA-ILD remains one of the most serious extra-articular manifestations of RA, contributing substantially to morbidity and mortality. Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.

Read Article
safety data

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal

By Mrinalini Dey, MD

Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.

Read Article
safety data

Upadacitinib: revisiting safety data in RA and GCA

By Mrinalini Dey, MD

For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive.

Read Article
microbiome,blue

Microbiome may hold key to methotrexate response in RA

By Mrinalini Dey, MD

Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) treatment, yet it remains unclear as to how to predict who will respond to it. Two studies presented at ACR (Abstracts 2639 and 2643) suggest the answer may be hiding in the gut.

Read Article
GLP-1.pink

GLP-1 Receptor Agonists: Impacts Beyond Metabolism?

By Mrinalini Dey, MD

The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.

Read Article
Fitbit

From Fitbit to first diagnosis: AI is rewriting the RA playbook

By Mrinalini Dey, MD

Artificial intelligence isn’t a distant frontier anymore. It’s here, and it appears able to detect signs of rheumatoid arthritis, possibly before we can clinically detect it. Two studies presented at this year’s ACR meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden.

Read Article
Puzzle pieces

ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

By Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

Read Article
puzzle.RA_.jpg

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials

By Mrinalini Dey, MD

Advances in the treatment of rheumatoid arthritis, particularly the treat-to-target strategy and the introduction of effective DMARDs, have improved the management of inflammation in RA. However, improved inflammatory markers do not always translate into a resolution of patients’ symptoms or improvements in functional capacity. A recent pooled analysis from the CareRA and CareRA2020 randomized controlled trials shed new light on this dissociation between biological disease control and patient-reported outcomes.

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Mrinalini Dey, MD
  • Mrinalini Dey, MD

  • Dr. Mrinalini Dey is a Clinical Research Fellow at the Centre for Rheumatic Diseases, King’s College London, UK. She is also a Fellow-In-Training in Rheumatology and General Internal Medicine.  She is currently pursuing a clinical PhD examining the role comorbidities and social determinants of health in outcomes in inflammatory arthritis.

    Since graduating from the University of Cambridge, in 2016, Mrinalini has pursued a clinical research career focussing on epidemiology, mixed-methods research and outcomes in inflammatory arthritis. Mrinalini sits on the Editorial Board and Digital and Social Media Committee for Rheumatology journal. She the Co-Chair of the Social Media Subcommittee of the Emerging EULAR Network (EMEUNET), as well as sitting on the EULAR People with Arthritis and Rheumatism in Europe (PARE) and Advocacy Committees. Mrinalini has a passion for teaching and science communication, and has previously been a reporter for RheumNow, as well as EULAR TV.

×